Cargando…
Prognostic and predictive factors associated with ipilimumab-related adverse events: a retrospective analysis of 11 NCI-sponsored phase I clinical trials
Background: We review factors impacting ipilimumab-associated adverse events through the experience from National Cancer Institute (NCI)-sponsored phase I immunotherapy clinical trials. Materials and Methods: Attributable ipilimumab-related adverse events from NCI-sponsored phase I immunotherapy cli...
Autores principales: | Chauhan, Aman, Kabir, Tanvir, Wu, Jianrong, Wei, Jing, Cook, Mary, Kunos, Charles A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185063/ https://www.ncbi.nlm.nih.gov/pubmed/32363000 http://dx.doi.org/10.18632/oncotarget.27537 |
Ejemplares similares
-
Immunotherapy for Medulloblastoma: Current Perspectives
por: Kabir, Tanvir F, et al.
Publicado: (2020) -
Ipilimumab in the treatment of metastatic melanoma: management of adverse events
por: Della Vittoria Scarpati, Giuseppina, et al.
Publicado: (2014) -
Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022) -
Enrollment of adolescent and young adult patients newly diagnosed with cancer in NCI CTEP‐sponsored clinical trials before and after launch of the NCI National Clinical Trials Network
por: Sankaran, Hari, et al.
Publicado: (2022) -
Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
por: Karimi, Amirali, et al.
Publicado: (2021)